Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.74 |
| ▸ | MMP13 | P45452 | 3/20 | 0.64 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL929039 | 0.85 | ADORA2A (1.00) | ADORA2AADORA1ADORA3ADORA2BALDH1A1 | |
| SCHEMBL2764459 | 0.84 | ADORA2A (0.73) | ADORA2AADORA1PTPN22CYP1A2CYP2D6 | |
| SCHEMBL2763924 | 0.82 | ADORA2A (0.75) | ADORA2AADORA1PTPN22CYP1A2CYP2D6 | |
| SCHEMBL929518 | 0.82 | ADORA2A (0.66) | ADORA2AADORA1ADORA3ADORA2BKDM4E | |
| SCHEMBL928179 | 0.82 | ADORA2A (0.74) | ADORA2AADORA1PTPN22ADORA3ADORA2B | |
| SCHEMBL13084738 | 0.81 | ADORA2A (0.70) | ADORA2AADORA1ADORA3ADORA2BMAPT | |
| SCHEMBL2763545 | 0.80 | ADORA2A (0.75) | ADORA2AADORA1PTPN22CYP1A2CYP2D6 | |
| SCHEMBL929303 | 0.80 | ADORA2A (0.73) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL929781 | 0.79 | ADORA2A (0.68) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL5719830 | 0.79 | ADORA2A (0.70) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | claimed |
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| EP-1722798-B1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONISTS | VERNALIS R&D LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| EP-1722798-B1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONISTS | VERNALIS R&D LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | VERNALIS (R&D) LTD. (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | VERNALIS (R&D) LTD. (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | VERNALIS (R&D) LTD. (GB) | 2008-07-31 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182860-A1 | Pyrimidine Compounds as Purine Receptor Antagonist | ADORA3, P2RY10, ADORA2A | ADORA2A 3/4885ADORA1 4/4885MMP13 4060/4885 |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885MMP13 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.